In adults with Philadelphia chromosome–positive ALL, the use of ABL-specific TK inhibitors, with or without systemic chemotherapy, allows most patients to have a complete hematologic response; a sustained decrease in minimal residual disease is associated with an increased chance of cure. New research findings are summarized in a short video. https://nej.md/3dx0Zmw | The New England Journal of Medicine